Liquidia Reports Strong 2025 Financial Performance with YUTREPIA Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy LQDA?
Source: Newsfilter
- Sales Growth: In 2025, YUTREPIA® achieved net product sales of $148.3 million, with fourth-quarter sales reaching $90.1 million, indicating strong market demand and product acceptance, thereby solidifying Liquidia's position in the specialty drug market.
- Profitability Improvement: The company recorded a net income of $14.6 million in the fourth quarter of 2025, marking its second consecutive profitable quarter, demonstrating rapid financial stability post-launch and enhancing its capacity for future investments and expansions.
- Strong Cash Position: As of December 31, 2025, Liquidia's cash and cash equivalents totaled $190.7 million, an increase of $33.2 million from the third quarter, ensuring financial flexibility for future R&D and marketing initiatives.
- Prescription Growth: Since its launch in June 2025, YUTREPIA has received over 3,600 unique prescriptions and treated more than 2,900 patients, with a prescription-to-start conversion rate maintained above 85%, reflecting high recognition and trust from both physicians and patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.870
Low
31.00
Averages
47.50
High
67.00
Current: 35.870
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LQDA Options Contract Analysis and Investment Opportunities
- Put Option Appeal: The current bid for the $35.00 put option is $9.80, and if an investor sells this contract, they commit to buying the stock at $35.00, effectively lowering their cost basis to $25.20, which represents a 4% discount from the current price of $36.65, making it attractive for those interested in LQDA.
- Return Potential: Should the put option expire worthless, the premium would yield a 28% return on cash commitment, or 36.11% annualized, making this investment strategy particularly appealing in the current market context.
- Call Option Returns: The $40.00 call option has a current bid of $10.10, and if an investor buys LQDA shares at $36.65 and sells this call, they could achieve a total return of 36.70% if the stock is called away at expiration, providing an additional revenue opportunity.
- Risk Assessment: Current data indicates a 35% chance that the $40.00 call option will expire worthless, allowing investors to retain both their shares and the premium collected, thereby enhancing the safety and return potential of their investment.
See More
Liquidia and Dianthus See Active Options Trading
- Liquidia Options Volume: Liquidia Corp (Ticker: LQDA) experienced an options trading volume of 9,692 contracts today, equating to approximately 969,200 shares, which represents about 48.1% of its average daily trading volume of 2 million shares over the past month, indicating heightened market interest in its future performance.
- High Call Option Activity: Among LQDA options, the $47.50 strike call option expiring on January 21, 2028, has seen particularly high activity with 3,100 contracts traded today, representing around 310,000 underlying shares, suggesting increased investor expectations for a price rise.
- Dianthus Options Trading: Dianthus Therapeutics Inc (Ticker: DNTH) recorded an options trading volume of 3,379 contracts today, equivalent to approximately 337,900 shares, which is about 48% of its average daily trading volume of 704,415 shares over the past month, reflecting market interest in its potential volatility.
- High Put Option Activity: The $50 strike put option for DNTH, expiring on March 20, 2026, has seen 1,659 contracts traded today, representing approximately 165,900 underlying shares, indicating investor concern regarding potential downside risks.
See More
Liquidia Corporation Reports Strong Q4 2025 Earnings and Growth Outlook
- Sales Growth: YUTREPIA achieved $148.3 million in net product sales for 2025, with $90.1 million in Q4 alone, reflecting a robust 74% growth over Q3 2025, indicating strong market demand and sales momentum.
- Profitability Improvement: The company reported $27.3 million in non-GAAP adjusted EBITDA and $14.6 million in net income for Q4, marking the second consecutive quarter of profitability growth, showcasing success in cost control and market expansion.
- Market Share Expansion: YUTREPIA's market share increased from 10% in Q3 2025 to 17% in Q4, demonstrating significant progress in a competitive landscape and further solidifying the company's market position.
- Future Development Plans: Liquidia plans to initiate multiple new studies in 2026 aimed at expanding product indications and further clinical validation, with management expressing strong confidence in achieving a $1 billion revenue target by 2027, reflecting a robust belief in future growth.
See More
Liquidia Reports Strong Q4 Results with YUTREPIA Traction
- Financial Highlights: Liquidia reported Q4 revenue of $92.02 million, exceeding analysts' expectations of $83.70 million, although its earnings per share (EPS) of $0.15 fell short of the $0.19 estimate, indicating strong revenue growth despite EPS challenges.
- Product Revenue Surge: The revenue from YUTREPIA is projected to reach approximately $148.3 million in 2025, with about $90.1 million generated in Q4 alone, showcasing significant early traction in the drug's commercial rollout.
- Positive Market Reaction: Following the earnings report, Liquidia's stock traded over 6% higher in Thursday's premarket, reflecting investor optimism regarding the company's growth potential.
- Strategic Implications: While EPS did not meet expectations, the robust revenue growth and favorable market response suggest that Liquidia is on a promising path in the commercialization of its respiratory drug, potentially laying the groundwork for sustained future growth.
See More
Liquidia Reports Q4 Earnings with Revenue Beat
- Earnings Performance: Liquidia reported a Q4 GAAP EPS of $0.15, missing expectations by $0.05, indicating potential pressure on profitability that may affect investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $92.02 million, reflecting a staggering 3051.4% year-over-year increase, surpassing market expectations by $4.53 million, demonstrating strong product demand and ongoing market share expansion.
- Market Outlook: Liquidia is poised for robust performance in the coming years, particularly with a strong outlook for 2026, highlighting its competitive advantages in specific markets.
- Industry Dynamics: Despite Liquidia's stock facing pressure due to United Therapeutics considering a new treprostinil formulation, the company is actively pursuing special situation gains and long-term growth opportunities.
See More
Liquidia Reports Strong 2025 Financial Performance with YUTREPIA Sales
- Sales Growth: In 2025, YUTREPIA® achieved net product sales of $148.3 million, with fourth-quarter sales reaching $90.1 million, indicating strong market demand and product acceptance, thereby solidifying Liquidia's position in the specialty drug market.
- Profitability Improvement: The company recorded a net income of $14.6 million in the fourth quarter of 2025, marking its second consecutive profitable quarter, demonstrating rapid financial stability post-launch and enhancing its capacity for future investments and expansions.
- Strong Cash Position: As of December 31, 2025, Liquidia's cash and cash equivalents totaled $190.7 million, an increase of $33.2 million from the third quarter, ensuring financial flexibility for future R&D and marketing initiatives.
- Prescription Growth: Since its launch in June 2025, YUTREPIA has received over 3,600 unique prescriptions and treated more than 2,900 patients, with a prescription-to-start conversion rate maintained above 85%, reflecting high recognition and trust from both physicians and patients.
See More
LQDA Options Contract Analysis and Investment Opportunities
- Put Option Appeal: The current bid for the $35.00 put option is $9.80, and if an investor sells this contract, they commit to buying the stock at $35.00, effectively lowering their cost basis to $25.20, which represents a 4% discount from the current price of $36.65, making it attractive for those interested in LQDA.
- Return Potential: Should the put option expire worthless, the premium would yield a 28% return on cash commitment, or 36.11% annualized, making this investment strategy particularly appealing in the current market context.
- Call Option Returns: The $40.00 call option has a current bid of $10.10, and if an investor buys LQDA shares at $36.65 and sells this call, they could achieve a total return of 36.70% if the stock is called away at expiration, providing an additional revenue opportunity.
- Risk Assessment: Current data indicates a 35% chance that the $40.00 call option will expire worthless, allowing investors to retain both their shares and the premium collected, thereby enhancing the safety and return potential of their investment.
See More
Liquidia and Dianthus See Active Options Trading
- Liquidia Options Volume: Liquidia Corp (Ticker: LQDA) experienced an options trading volume of 9,692 contracts today, equating to approximately 969,200 shares, which represents about 48.1% of its average daily trading volume of 2 million shares over the past month, indicating heightened market interest in its future performance.
- High Call Option Activity: Among LQDA options, the $47.50 strike call option expiring on January 21, 2028, has seen particularly high activity with 3,100 contracts traded today, representing around 310,000 underlying shares, suggesting increased investor expectations for a price rise.
- Dianthus Options Trading: Dianthus Therapeutics Inc (Ticker: DNTH) recorded an options trading volume of 3,379 contracts today, equivalent to approximately 337,900 shares, which is about 48% of its average daily trading volume of 704,415 shares over the past month, reflecting market interest in its potential volatility.
- High Put Option Activity: The $50 strike put option for DNTH, expiring on March 20, 2026, has seen 1,659 contracts traded today, representing approximately 165,900 underlying shares, indicating investor concern regarding potential downside risks.
See More
Liquidia Corporation Reports Strong Q4 2025 Earnings and Growth Outlook
- Sales Growth: YUTREPIA achieved $148.3 million in net product sales for 2025, with $90.1 million in Q4 alone, reflecting a robust 74% growth over Q3 2025, indicating strong market demand and sales momentum.
- Profitability Improvement: The company reported $27.3 million in non-GAAP adjusted EBITDA and $14.6 million in net income for Q4, marking the second consecutive quarter of profitability growth, showcasing success in cost control and market expansion.
- Market Share Expansion: YUTREPIA's market share increased from 10% in Q3 2025 to 17% in Q4, demonstrating significant progress in a competitive landscape and further solidifying the company's market position.
- Future Development Plans: Liquidia plans to initiate multiple new studies in 2026 aimed at expanding product indications and further clinical validation, with management expressing strong confidence in achieving a $1 billion revenue target by 2027, reflecting a robust belief in future growth.
See More
Liquidia Reports Strong Q4 Results with YUTREPIA Traction
- Financial Highlights: Liquidia reported Q4 revenue of $92.02 million, exceeding analysts' expectations of $83.70 million, although its earnings per share (EPS) of $0.15 fell short of the $0.19 estimate, indicating strong revenue growth despite EPS challenges.
- Product Revenue Surge: The revenue from YUTREPIA is projected to reach approximately $148.3 million in 2025, with about $90.1 million generated in Q4 alone, showcasing significant early traction in the drug's commercial rollout.
- Positive Market Reaction: Following the earnings report, Liquidia's stock traded over 6% higher in Thursday's premarket, reflecting investor optimism regarding the company's growth potential.
- Strategic Implications: While EPS did not meet expectations, the robust revenue growth and favorable market response suggest that Liquidia is on a promising path in the commercialization of its respiratory drug, potentially laying the groundwork for sustained future growth.
See More
Liquidia Reports Q4 Earnings with Revenue Beat
- Earnings Performance: Liquidia reported a Q4 GAAP EPS of $0.15, missing expectations by $0.05, indicating potential pressure on profitability that may affect investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $92.02 million, reflecting a staggering 3051.4% year-over-year increase, surpassing market expectations by $4.53 million, demonstrating strong product demand and ongoing market share expansion.
- Market Outlook: Liquidia is poised for robust performance in the coming years, particularly with a strong outlook for 2026, highlighting its competitive advantages in specific markets.
- Industry Dynamics: Despite Liquidia's stock facing pressure due to United Therapeutics considering a new treprostinil formulation, the company is actively pursuing special situation gains and long-term growth opportunities.
See More
Liquidia Reports Strong 2025 Financial Performance with YUTREPIA Sales
- Sales Growth: In 2025, YUTREPIA® achieved net product sales of $148.3 million, with fourth-quarter sales reaching $90.1 million, indicating strong market demand and product acceptance, thereby solidifying Liquidia's position in the specialty drug market.
- Profitability Improvement: The company recorded a net income of $14.6 million in the fourth quarter of 2025, marking its second consecutive profitable quarter, demonstrating rapid financial stability post-launch and enhancing its capacity for future investments and expansions.
- Strong Cash Position: As of December 31, 2025, Liquidia's cash and cash equivalents totaled $190.7 million, an increase of $33.2 million from the third quarter, ensuring financial flexibility for future R&D and marketing initiatives.
- Prescription Growth: Since its launch in June 2025, YUTREPIA has received over 3,600 unique prescriptions and treated more than 2,900 patients, with a prescription-to-start conversion rate maintained above 85%, reflecting high recognition and trust from both physicians and patients.
See More
